Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC

Clinical trial NCT05557838 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05557838
Sponsor: AstraZeneca
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Hepatocellular Carcinoma

Start date: 2023-02-15
Primary completion: 2026-09-30
Enrollment: 214

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.